Validation of combined carcinoembryonic antigen and glucose testing in pancreatic cyst fluid to differentiate mucinous from non-mucinous cysts
Open Access
- 19 January 2023
- journal article
- research article
- Published by Springer Nature in Surgical Endoscopy
- Vol. 37 (5) , 3739-3746
Abstract
Background: More accurate diagnosis of mucinous cysts will reduce the risk of unnecessary pancreatic surgery. Carcinoembryonic antigen (CEA) and glucose in pancreatic cyst fluid (PCF) can differentiate mucinous from non-mucinous pancreatic cystic neoplasms (PCN). The current study assessed the value of combined CEA and glucose testing in PCF. Methods: Cross-sectional validation study including prospectively collected PCF from patients undergoing endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) and pancreatic surgery. We performed laboratory measurements for CEA and glucose and measured glucose levels by a hand glucometer. Primary outcome was diagnostic accuracy evaluated by receiver operator curves (ROC), sensitivity, specificity, positive, and negative predictive value (PPV, NPV). Results: Overall, PCF was collected from 63 patients, including 33 (52%) with mucinous and 30 (48%) with non-mucinous PCN. Histopathology (n = 36; 57%), cytopathology (n = 2; 3%), or clinical and/or radiological diagnosis (n = 25; 40%) was used as reference standard. Combined CEA (cut-off ≥ 192 ng/ml) and laboratory glucose testing (cut-off ≤ 50 mg/dL) reached 92% specificity and 48% sensitivity, whereas either positive CEA (cut-off ≥ 20 ng/ml) or glucose testing (cut-off ≤ 50 mg/dL) showed 97% sensitivity and 50% specificity. Sensitivity and specificity were 80% and 68% for CEA ≥ 20 ng/mL versus 50% and 93% for CEA ≥ 192 ng/mL (the conventional cut-off level). Laboratory and glucometer glucose both reached 100% sensitivity and 60% and 45% specificity, respectively. None of the biomarkers and cut-offs reached a PPV exceeding 90%, whereas both glucose measurements had a NPV of 100% (i.e., high glucose excludes a mucinous cyst). Conclusion: Combined CEA and glucose testing in PCF reached high specificity and sensitivity for differentiating mucinous from non-mucinous PCN. Glucose testing, whether alone or combined with the new CEA cut-off (≥ 20 ng/mL), reached > 95% sensitivity for mucinous cysts, whereas only glucose reached a NPV > 95%. GraphicalKeywords
This publication has 15 references indexed in Scilit:
- Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelinesNature Reviews Gastroenterology & Hepatology, 2019
- THE DIAGNOSTIC ACCURACY OF CARCINOEMBRYONIC ANTIGEN IN DIFFERENTIATING MUCINOUS AND NON-MUCINOUS PANCREATIC CYSTIC NEOPLASMS – A SYSTEMATIC REVIEW AND INDIVIDUAL PATIENT DATA META-ANALYSISEndoscopy, 2018
- European evidence-based guidelines on pancreatic cystic neoplasmsGut, 2018
- Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based studyGut, 2017
- Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreasPancreatology, 2017
- Comparing 3 guidelines on the management of surgically removed pancreatic cysts with regard to pathological outcomeGastrointestinal Endoscopy, 2017
- Suboptimal accuracy of carcinoembryonic antigen in differentiation of mucinous and nonmucinous pancreatic cysts: results of a large multicenter studyGastrointestinal Endoscopy, 2015
- STARD 2015: an updated list of essential items for reporting diagnostic accuracy studiesBMJ, 2015
- Cyst Fluid Glucose is Rapidly Feasible and Accurate in Diagnosing Mucinous Pancreatic CystsAmerican Journal of Gastroenterology, 2015
- Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst studyGastroenterology, 2004